

STOP

Before opening this package, please read the Limited Use License statement below:

Important Limited Use License information for pCpGfree-Lucia

The purchase of the pCpGfree-Lucia vector conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The buyer cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for Commercial Purposes.

The buyer may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any Commercial Purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for Commercial Purposes.

Commercial Purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic, or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research.

If the purchaser is unwilling to accept the limitations of this limited use statement, InvivoGen is willing to accept return of the product with a full refund. The product must be returned in resaleable condition. For information on purchasing a license to this product for purposes other than research, contact InvivoGen, 10515 Vista Sorrento Parkway San Diego, CA 92121 USA. Tel: 858-457-5873 Fax: 858-457-5843.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3-622-34-80
E-mail: info@invivogen.com



pCpGfree-Lucia

A Lucia® expression plasmid completely devoid of CpG dinucleotides

Catalog # pcpgf-lucia

For research use only

Version 21F04-MMv02

PRODUCT INFORMATION

Content:

- 20 µg of pCpGfree-Lucia plasmid provided as lyophilized DNA
- *E. coli* GT115 strain provided lyophilized on a paper disk
- 1 ml of Zeocin™ (100 mg/ml)

Storage and Stability:

- Products are shipped at room temperature.
- Lyophilized DNA is stable 1 year when stored at -20 °C.
- Resuspended DNA is stable 6 months when stored at -20 °C.
- Bacteria should be stored at -20 °C and are stable up to 1 year.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

Plasmid construct has been confirmed by restriction analysis and sequencing. Plasmid DNA was purified by ion exchange chromatography and lyophilized. Viability of the lyophilized bacteria upon resuspension has been verified.

GENERAL PRODUCT USE

InvivoGen has developed a new family of plasmids that are completely devoid of CpG dinucleotides. These plasmids yield high levels of transgene expression both *in vitro* and *in vivo*, and in contrast to CMV-based plasmids allow sustained expression *in vivo*.

pCpG plasmids contain elements that naturally lack CpG dinucleotides, were modified to remove all CpGs, or entirely synthesized such as genes encoding selectable markers or reporters.

pCpG plasmids represent valuable tools to study the effects of CpGs on gene expression *in vivo* and *in vitro*, using cell lines expressing TLR9, as well as their effects on the innate and acquired immune systems. Furthermore, for RNAi applications, InvivoGen has designed pCpG-siRNA a plasmid that allows long term production of siRNAs *in vivo*.

PLASMID FEATURES

All the elements required for replication and selection of the plasmid in *E. coli* and gene expression in mammalian cells are completely devoid of CpG dinucleotides.

Elements for expression in *E. coli*

- Origin of replication: The *E. coli* R6K gamma ori has been modified to remove all CpGs. This origin is activated by the R6K specific initiator protein π , encoded by the *pir* gene¹.
- Bacterial promoter: EM2K is a CpG-free version of the bacterial EM7 promoter.
- Selectable marker: The Zeocin™ resistance gene is a small gene (<400 bp) that contains numerous CpG dinucleotides. A synthetic new allele was created that contains no CpGs.

Elements for expression in mammalian cells

- Mammalian promoter: The CpG-free promoter combines the mouse CMV enhancer, the human elongation factor 1 alpha core promoter and 5'UTR containing a synthetic intron.
- Polyadenylation signal: The polyadenylation signal is a CpG-free form of the late SV40 polyadenylation signal.

- MAR: Matrix attached regions (MARs) are sequences typically AT-rich that are able to form barriers between independently regulated domains². pCpG plasmids contains two MARs, from the 5' region of the human IFN- β gene or β -globin gene that were chosen because they are naturally CpG-free. The MARs are placed between the bacterial and mammalian transcription units.
- Lucia luciferase is a synthetic CpG-free gene that codes for a secreted coelenterazine-utilizing luciferase.
ORF size (from the ATG to the stop codon): 634 bp

Due to the presence of the R6K γ origin of replication, pCpG plasmids can only be amplified in *E. coli* mutant strain expressing a *pir* mutant gene. They will not replicate in standard *E. coli* strains. Therefore, pCpG plasmids are provided with the *E. coli* GT115 strain, a *pir* mutant also deficient in *Dcm* methylation.

1. Wu F. *et al.* 1995. A DNA segment conferring stable maintenance on R6K gamma-origin core replicons. *J Bacteriol.* 177(22):6338-45. 2. Bode J. *et al.*, 1996. Scaffold/matrix-attached regions: topological switches with multiple regulatory functions. *Crit Rev Eukaryot Gene Expr.* 6(2-3):115-38.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Reconstitution of *E. coli* GT115 strain

Use sterile conditions to do the following:

1. Reconstitute *E. coli* GT115 by adding 1 ml of Luria-Bertani (LB) medium in the tube containing the paper disk. Let sit for 5 minutes.
2. Mix gently by vortexing for 1-2 minutes.
3. Streak bacteria taken from this suspension on a LB agar plate.
4. Place the plate in an incubator at 37 °C overnight.
5. Isolate a single colony and grow the bacteria in LB or terrific broth (TB) medium.
6. Prepare competent cells utilizing protocol of choice.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT115.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3-622-34-80
E-mail: info@invivogen.com




RELATED PRODUCTS

Product	Catalog Code
QUANTI-Luc™	rep-qlc1
ChemiComp GT115	gt115-11
pCpGfree-mcs	pcpgf-mcs
pCpGfree-LacZ	pcpgf-lacz
pCpGfree-mSEAP	pcpgf-mseap
pCpGrich-mcs (CpG-containing control plasmid)	pcpgr-mcs

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Hong Kong: +852 3-622-34-80
E-mail: info@invivogen.com



1 Pacl (-1)
 1 TTAATTAATAATTATCTCTAAGGCATGTGAAGTGGCTGCTTGGTTTTTCATCTGTACTTTCATCTGCTACCTCTGTGACCTGAAACATATTTATAATTCCAT
 101 TAAGCTGTGCATATGATAGATTATCATATGATTTTTCTTAAAGGATTTTTGTAAGAACTAATTGAATTGATACCTGTAAGTCTTTATCACACTACCC
 201 AATAAATAATAAATCTTTTGTTCAGCTCTCTGTTTCTATAAATATGTACCAGTTTTATTGTTTTTAGTGGTAGTGATTTTATTCTCTTTCTATATATAT
 301 ACACACACATGTGTGCATTATAAATATATAACAATTTTTATGAATAAAAAAATTATTAGCAATCAATATTGAAAACCACTGATTTTTGTTTTATGTGAGCAA

 SdaI (420)
 EcoRI (415)
 401 ACAGCAGATTAATAAGGAATTCCTGCAGGAGTCAATGGGAAAAACCCATTGGAGCCAAGTACACTGACTCAATAGGGACTTTCCATTGGGTTTTGCCCAGT
 501 ACATAAGGTCAATAGGGGGTGAAGTCAACAGGAAAGTCCCATTGGAGCCAAGTACATTGAGTCAATAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAG
 601 GTCAATGGGAGGTAAAGCAATGGGTTTTTCCCATTACTGACATGATACTGAGTCAATAGGGACTTTCCAATGGGTTTTGCCCAGTACATAAGGTCAATA
 701 GGGGTGAATCAACAGGAAAGTCCCATTGGAGCCAAGTACACTGAGTCAATAGGGACTTTCCATTGGGTTTTGCCCAGTACAAAAGGTCAATAGGGGGTGA

 SpeI (850)
 801 GTCAATGGGTTTTTCCCATTATTGGCACATACATAAGGTCAATAGGGGTGACTAGTGGAGAAGAGCATGCTTGAGGGCTGAGTGCCCTCAGTGGGCAGA
 901 GAGCACATGGCCACAGTCCCTGAGAAGTTGGGGGAGGGGTGGCAATTGAACTGGTGCCTAGAGAAGTTGGGGCTGGGTAAGTGGGAAAGTATGATG

 HindIII (1074)
 1001 GGTGTACTGGCTCCACCTTTTTCCCCAGGGTGGGGGAGAACCATATATAAGTGCAGTAGTCTGTGAACATTCAAGCTTCTGCCTTCTCCCTCCTGTGA
 1101 GTTTGgtaagtcactgactgtctatgctgggaaaggggtgggcaggaggtggggcagtgaggaaaagtggcactgtgaacctgcagccctagacaatt

 NcoI (1254)
 1201 gtactaaccttcttctcttctctctctgacagGTTGGTGTACAGTAGCTCCACCATGGAAATCAAGGTGCTGTTGCCCTCATCTGTATTGCTGTTGC
 1▶ M E I K V L F A L I C I A V A

 BglIII (1369)
 1301 TGAGGCAAAACCCACTGAAATCAATGAAGACCTCAATATAGCTGCTGTGGCTCCAACCTTGGCACCACAGATCTTGAGACTGACCTGTTCCACCACTGG
 15▶ E A K P T E I N E D L N I A A V A S N F A T T D L E T D L F T N W
 1401 GAGACCATGAATGTGATTAGCACTGACACAGAGCAGGTGAACACAGATGCTGACAGGGCAAGCTGCCTGGCAAAAACTCCCCCAGATGCTCCTGAGGG
 49▶ E T M N V I S T D T E Q V N T D A D R G K L P G K K L P P D V L R
 1501 AGCTGGAGGCCAATGCCAGAAGGGCTGGTTGCACAAGAGGCTGCCTCATTGCTCTCCACATTAAGTGCACCCCTAAGTGAAGAAATTTATCCCTGG
 82▶ E L E A N A R R A G C T R G C L I C L S H I K C T P K M K K F I P G

 EcoRV (1664)
 1601 CAGGTGCCACACTTATGAAGGTGAAAAGGAGTCTGCTCAGGGAGGGATTGGAGAGGCAATTGTTGATATCCAGAGATTCTGGCTTCAAGGATAAGGAG
 115▶ R C H T Y E G E K E S A Q G G I G E A I V D I P E I P G F K D K E
 1701 CCACTGGACCAGTTTATTGCTCAAGTGGACCTCTGTGCTGATTGCACCACTGGCTGTCTGAAGGGCCTTGCCAATGTCCAGTGTCTGACCTCCTGAAGA
 149▶ P L D Q F I A Q V D L C A D C T T G C L K G L A N V Q C S D L L K

 NheI (1888)
 1801 AGTGGCTTCCCAGAGGTGTACCACTTTTCCAGCAAGATTGAGGGTAGGGTGGACAAAATCAAGGGTCTGGCTGGGGACAGATGATAGCTAGCTGGCCAA
 182▶ K W L P Q R C T T F A S K I Q G R V D K I K G L A G D R •
 1901 GACATGATAAGATACATTGATGAGTTGGACAAACCACAAGTGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTG
 2001 TAACCATTATAAGCTGCAATAAACAAGTTAAACAACAATTGCATTCATTTTATGTTTCAGGTTTCAGGGGAGGTGTGGGAGGTTTTTAAAGCAAGTA

 EcoRI (2122)
 2101 AAACCTTACAAATGTGGTATGGAATTCAGTCAATATGTTACCCCAAAAAAGCTGTTGTTAACTTGCCAACCTCATTCTAAAATGTATATAGAAGCCC
 2201 AAAAGACAATAACAAAAATATCTTGTAGAACAAAATGGGAAAGAATGTTCCACTAAATATCAAGATTAGAGCAAAGCATGAGATGTGTTGGGATAGAC

 SacI (2323)
 2301 AGTGAGGCTGATAAATAGAGTAGAGCTCAGAAACAGACCCATTGATATATGTAAGTACCTATGAAAAAATATGGCATTTCACAATGGGAAAATGATG
 2401 GTCTTTTTCTTTTTAGAAAAACAGGAAATATATTTATATGTAAAAAATAAAGGGAACCCATATGTCATACCATACACAAAAAATCCAGTGAAT
 2501 TATAAGTCTAAATGGAGAAGGCAAACTTTAAATCTTTAGAAAAATAATAGAACATGCCATCAAGACTTCAGTGTAGAGAAAAATTTCTTATGACTC
 2601 AAAGTCTAACCAAGAAAAGATTGTTAATTAGATTGCATGAATATTAAGACTTATTTTTAAAATTAATAAACCAATTAAGAAAAGTCAAGCCATAGAA
 2701 TGACAGAAAATATTTGCAACACCCAGTAAAGAGAATTGTAATATGCAGATTATAAAAAAGAGTCTTACAATCAGTAAAAAATAAACTAGACAAAAAT
 2801 TTGAACAGATGAAAGAGAACTCTAATAATCATTACACATGAGAACTCAATCTCAGAAATCAGAGAACTATCATTGCATATACACTAAATTAGAGAAA

PacI (2928)

2901 TATTTAAAGGCTAAGTAACATCTGTGGCTTAATTTAAATCAGCAGTTCAACCTGTTGATAGTATGACTAAGCTCTCATGTTTAAATGACTAAGCTCTCA
3001 TGTTTAATGAACTAAACCCTCATGGCTAATGACTAAGCTCTCATGGCTAATGACTAAGCTCTCATGTTTCATGACTAAGCTCTCATGTTTGAACAAT

AseI (3103)

3101 AAAATTAATATAAATCAGCAACTTAAATAGCCTCTAAGGTTTTAAGTTTTATAAGAAAAAAGAATATATAAGGCTTTTAAAGGTTTTAAGGTTTCCTA

3201 GCTTTAGTCCTGTTCTCAGCTACAAAATGGACACAATTCAGCAGGGTCTCTGAGGGCAAATCCCTTCCCAAGTTGTTACCAATTTCTGTCATG
125 • D Q E E A V F H V C N G A P D R L A F E R G W P Q E G I E T M
3301 GCTGGCCAGAGGCATCCCTGAAATTTGTGCTGACTACTTCTGACCATTCTGCATAAAGCTCATCTAGGCCTCTGACCCAGACCAAGCAAGGGTGTGT
92 A P G S A D R F N T S V V E S W E A Y L E D L G R V W V W A L T N D
3401 CAGGGACAACCTGGTCTGAACTGCTGAGATGAAGAGGGTGACATCATCTCTGACAACACCAGCAAAATCATCTTCAACAAAGTCTCTGGAGAATCCTAA
59 P V V Q D Q V A S I F L T V D D R V V G A F D D E V F D R S F G L

SfiI (3572)

3501 TCTGTCACTCCAGAAGTCTACAGCCCTGCAACATCCCTTGCTGTGAGGACTGGGACTGCAGAAGTGAGTTTGGCCATGATGGCCCTCTATAGTGAGTT
26 R D T W F E V A G A V D R A T L V P V A S T L K A M
3601 GTATTATACTATGCAGATATACTATGCCAATGTTAATTGTCAACTACCTGTT